It’s worth reflecting that it has been more than two years since the COVID-19 pandemic began. Let’s look back to the months of early to mid-2020 when the nation (and the rest of the world) faced a “novel” coronavirus, one which we knew could be fatal and for which there was little knowledge about how it spreads and no known effective treatment, limited diagnostic tests, and no vaccine. How did NIH make fast and meaningful contributions to respond to the pandemic?
Open Mike Perspective: Healthy Skepticism when Focusing Solely on Surrogate Endpoints in Clinical Research
I recently wrote an essay for the NIH’s Science, Health, and Public Trust series to encourage a healthy bit of skepticism about clinical studies that solely involve surrogate end-points (e.g. changes in “biomarkers” like blood cholesterol levels or findings on an electrocardiogram).